PBAC's latest decision on Capecitabine, megestrol, toremifene, vinorelbine: Recommended with restriction (2014). Considered for Multiple indications across four chemotherapy agents: capecitabine for advanced breast cancer and colorectal cancer; megestrol for hormone-dependent advanced breast cancer; toremifene for hormone-dependent metastatic breast cancer in post-menopausal patients; vinorelbine for locally advanced/metastatic non-small cell lung cancer and advanced breast cancer.
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Patients with advanced/metastatic breast cancer, colorectal cancer, oesophago-gastric cancer, and non-small cell lung cancer (various lines of therapy as per existing PBS restrictions).
Therapy area
Oncology
Line of therapy
Later-line
Economic model
Not modelled
ICER note
Not modelled — this is a restriction level change request for existing PBS-listed drugs, not a new submission with economic evaluation.